A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymphoma (NHL) (NCT04903197)
CVAY736J12101
This trial is No longer recruiting
Registration number NCT04903197
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Maciej Tatarczuch
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.